Woodcock Defends Speed Of FDA Reviews, Cites 20 Approvals In First Half Of 2011

As House begins hearings on PDUFA V, industry and venture capitalists say agency policies pre-NDA submission slow drug development.

More from Archive

More from Pink Sheet